Condition: Membranous Nephropathy · Sponsor: Mario Negri Institute for Pharmacological Research
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice. The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.
This description comes directly from the study's public registry record.
Matias Trillini, MD · +3903545351 · matias.trillini@marionegri.it
Piero L Ruggenenti, MD · pruggenenti@asst-pg23.it
Always discuss trial participation with your own doctor first.
| ASST HPG23 - Unità di Nefrologia | Bergamo, BG, Italy | Active Not Recruiting |
| Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò" | Ranica, BG, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06242327